GB491 Combined With Fulvestrant for HR+ HER2- Locally Advanced or Metastatic Breast Cancer
|
|
文献详情
编号/登记号：
注册时间：
研究开始时间：
研究结束时间：
项目类型：
本院角色：
多中心研究：
招募状态：
试验分期：
研究疾病/适应症：
研究类型：
研究单位：[1]Genor Biopharma Co., Ltd.[2]Anhui Provincial Cancer Hospital Hefei, Anhui, China, 230031[3]The Second Hospital of Anhui Medical University Hefei, Anhui, China, 230601[4]Beijing Chaoyang Hospital of Capital Medical University Beijing, Beijing, China, 100020[5]Cancer hospital Chinese Academy of Medical Sciences Beijing, Beijing, China, 100021[6]Chinese PLA General Hospital Beijing, Beijing, China, 100039[7]Beijing Tiantan Hospital , Capital Medical University Beijing, Beijing, China, 100050[8]Chongqing University Cancer Hospital Chongqing, Chongqing, China, 400030[9]The First Affiliated Hospital of Chongqing Medical University Chongqing, Chongqing, China, 400042[10]Chognqing University Three Gorges Hospital Chongqing, Chongqing, China, 404000[11]Fujian Medical University Union Hospital Fuzhou, Fujian, China, 350001[12]First Affiliated Hospital of Xiamen University Xiamen, Fujian, China, 361003[13]The First people's hospital of Foshan Foshan, Guangdong, China, 528000[14]Sun Yat-sen University Cancer Center Guangzhou, Guangdong, China, 510060[15]The First Affiliated Hospital, Sun Yat-sen University Guangzhou, Guangdong, China, 510080[16]Guangdong provincial TCM hospital Guangzhou, Guangdong, China, 510120[17]Meizhou People's Hospital Meizhou, Guangdong, China, 514031[18]Cancer Hospital Chinese Academy of Medical Sciences,Shenzhen Center Shenzhen Cancer Hospital Shenzhen, Guangdong, China, 518172[19]Hainan General Hospital Haikou, Hainan, China, 570311[20]Hainan Third People's Hospital Sanya, Hainan, China, 572000[21]The Fourth Hospital of Hebei Medical University Shijiazhuang, Hebei, China, 50011河北医科大学第四医院[22]Affiliated hospital of Hebei University Shijiazhuang, Hebei, China, 500311[23]Harbin Medcial Univercity cancer hospital Haerbin, Heilongjiang, China, 150081[24]Henan Cancer Hospital Zhengzhou, Henan, China, 450003[25]The First Affiliated Hospital of Zhengzhou University Zhengzhou, Henan, China, 450052[26]Tongji Medical College of Huazhong University of Science and Technology Wuhan, Hubei, China, 430022[27]Renmin Hospital of Wuhan University Wuhan, Hubei, China, 430060[28]Hubei Cancer Hospital Wuhan, Hubei, China, 430079[29]The Affiliated hospital of Inner Mongolia Medical University Hohhot, Inner Mongolia, China, 750306[30]Jiangsu Province Hospital Nanjing, Jiangsu, China, 210029[31]Jiangxi Provincial Hospital Nanchang, Jiangxi, China, 330029[32]Jilin Cancer Hospital Changchun, Jilin, China, 130012[33]The Second Hospital of Jilin University Changchun, Jilin, China, 130041[34]Bethune First Hospital Of Jilin University Changchun, Jillin, China, 130061[35]Shengjing Hospital of China Medical University Shenyang, Liaoning, China, 110022[36]Liaoning Cancer hospital & Institute Shenyang, Liaoning, China, 110801[37]General Hospital of Ningxia Medical University Yinchuan, Ningxia, China, 750003[38]Central Hospital Affiliated to Shandong First Medical University Jinan, Shandong, China, 250013[39]Shandong Provincial Qianfoshan Hospital Jinan, Shandong, China, 250013[40]Shandong Provincial Hospital Jinan, Shandong, China, 250021[41]Shandong Cancer Hospital Jinan, Shandong, China, 250117[42]Affiliated hospital of Jining Medical University Jining, Shandong, China, 272007[43]Liaocheng People's Hospital Liaocheng, Shandong, China, 252004[44]The Affiliated Hospital of Qingdao University Qingdao, Shandong, China, 266003[45]Taian City Central Hospital Taian, Shandong, China, 271099[46]Yantai Yuhuangding Hospital Yantai, Shandong, China, 264099[47]Zhongshan Hospital Fudan University Shanghai, Shanghai, China, 200030[48]The first hospital of Shanxi Medical University Taiyuan, Shanxi, China, 003001[49]West China School of Medicine Chengdu, Sichuan, China, 610044[50]Tianjin Medical University Cancer Institute & Hospital Tianjin, Tianjin, China, 300181[51]Affiliated Cancer Hospital of Xinjiang Medical University Urumqi, Xinjiang, China, 830011[52]The Third Affiliated Hospital of Kunming Medical University Kunming, Yunnan, China, 650118[53]The Second Affiliated Hospital, Zhejiang University School of Medicine Hangzhou, Zhejiang, China, 310003[54]Zhejiang Cancer Hospital Hangzhou, Zhejiang, China, 310005[55]The First Affiliated Hospital of Bengbu Medical College Bengbu, Anhui, China, 233099
GB491-004 is a multicenter, randomized, double-blind, placebo-controlled Phase III study to evaluate the efficacy and safety of GB491 in combination with fulvestrant in patients with HR-positive, HER2-negative locally advanced or metastatic breast cancer who have progressed on prior endocrine therapy.
